CI

At a glance

ClinicalIndex Comparison Record
Phase 1Active· 9 enrolled
Drug / intervention
Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04015700
NCT04015700Phase 1Active
CompareCT.gov

A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Washington University School of Medicine·interventional·Posted Jul 11, 2019·Updated May 7, 2026

In Brief

A Phase 1 clinical trial evaluating Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics, CELLECTRA®2000 EP Device supplied by Geneos Therapeutics, and 1 other intervention for Glioblastoma. Active but no longer recruiting, targeting 9 participants across 1 site.

Detailed Summary

This is a single institution, open-label, single arm, study assessing the safety, feasibility, and immunogenicity of a personalized neoantigen-based vaccine in subjects with newly diagnosed, unmethylated glioblastoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
CountriesUnited States
CollaboratorsGeneos Therapeutics, The Foundation for Barnes-Jewish Hospital, National Institute of Neurological Disorders and Stroke (NINDS)

Timeline

Phase 1Active
20202021202220232024202520262027
First PostedJul 11, 2019
Enrollment StartJul 14, 2020
Primary CompletionMay 13, 2022
Study CompletionSep 3, 2027
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.0 years ago

Interventions

Personalized neoantigen DNA vaccine supplied by Geneos Therapeuticsbiological

-The neoantigen DNA vaccines are also known as DNA plasmid vector expressing tumor-specific antigens.

CELLECTRA®2000 EP Device supplied by Geneos Therapeuticsdevice

CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.

Plasmid encoded IL-12drug

The INO-9012 vials will be supplied by Geneos Therapeutics